
Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.

Diana Cirstea, MD, is an attending physician in the Center for Multiple Myeloma at Massachusetts General Hospital, as well as an assistant professor of medicine at Harvard Medical School.

May 20th 2026